Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study

• Main Authors: Christopher John Wynne (Author), Alexandra Cole (Author), Charlotte Lemech (Author), Guoqin Wang (Author), Yu Zhang (Author), Benchao Chen (Author), Max Wang (Author), Baiyong Li (Author), Michelle Xia (Author), Rodney Sinclair (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Interleukin-4 (IL-4) and interleukin-13 (IL-13) are two essential cytokines involved in the T helper 2 (Th2)-mediated inflammatory response to diseases, such as atopic dermatitis (AD). AK120 is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) directed ag...